Navigation Links
Two Luminaries Join Cequent Scientific Advisory Board: Judy Lieberman, M.D. Ph.D., and Patrice Courvalin, M.D.
Date:10/6/2008

expert in translational medicine, and a pioneer in the therapeutic use of RNAi, particularly through the development of innovative delivery tools. The Lieberman laboratory at Harvard was the first to demonstrate that RNAi could be used to treat disease in an animal model. Dr. Lieberman and her colleagues are currently working to harness RNAi for use against HIV and other viruses and they have developed novel strategies for cell-specific targeting of small interfering RNAs to confer in vivo protection from viral disease. In related work, Dr. Lieberman's laboratory is also working in the emerging field of miRNAs by developing their potential as diagnostic and therapeutic tools.

Professor Patrice Courvalin, M.D., is head of the Antibacterial Agents Unit at the Institut Pasteur, Paris, France, where he directs the French National Reference Center for Antibiotics. He is an internationally recognized expert in the genetics and biochemistry of antibiotic resistance and in the transfer and heterologous expression of genetic information. He received master's degrees in sciences and in human biology from the University of Sciences in Paris and his doctorate in medical sciences from the Medical School in Paris. His research has led to a revision of the dogma describing natural dissemination of genes. In particular, he and his colleagues demonstrated that a wide variety of bacteria can promiscuously exchange genetic material and they proved that conjugation could account for dissemination of genes between phylogenetically remote bacterial genera. Because of his long-term interest in horizontal gene transfer among bacteria, Dr. Courvalin has been a thought leader in the area of using bacteria as intracellular vectors for delivery of DNA or proteins into mammalian cells. His laboratory was the first to describe the combination of invasin and listeriolysin to enable Escherichia coli as a gene therapy tool.

About Cequent Pharmaceuticals, Inc.

SOURCE Cequent Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Michael D. Taylor, Ph.D., Joins Cequent Pharmaceuticals Board of Directors
2. Cequent Pharmaceuticals Meets Novartis Option Fund Milestone; Continues to Next Phase to Validate Inflammatory Bowel Disease Targets in Vivo
3. Boston Scientific to Explore Sale of Cardiac Surgery and Vascular Surgery Businesses
4. Thermo Fisher Scientific Executive Officers Adopting SEC Rule 10b5-1 Trading Programs
5. Kewaunee Scientific Announces First Quarter Results and Quarterly Dividend
6. Ralf Rosskamp, M.D. Joins Biodels Scientific Advisory Board
7. Boston Scientific Amends Credit Facility and Prepays $1 Billion on Loan
8. Magellan Biosciences Names Steven E. Diamond, PhD, Chief Scientific Officer
9. Thermo Fisher Scientific to Present at Investor Conferences
10. Boston Scientific to Participate in the Bear Stearns 20th Annual Healthcare Conference
11. Dr. Keith Wilson Named President and Chief Scientific Officer of Takeda San Diego
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... ... September 02, 2015 , ... ... compliance, quality systems, analytical testing, education and consulting services for the medical ... medical device products/processes development, design control, validation, quality assurance and regulatory compliance. ...
(Date:9/2/2015)... DUBLIN , Sep. 02, 2015 ... ) has announced the addition of Jain PharmaBiotech,s ... Markets and Companies" to their offering. ... markets based on technologies and applications. The report ... basis for estimation of markets. Technologies include array ...
(Date:9/2/2015)... Research and Markets ... Jain PharmaBiotech,s new report "Biomarkers - Technologies, ... This report follows the broad definition of ... objectively measured and evaluated as an indicator of ... pharmacological responses to a therapeutic intervention. Tests based ...
(Date:9/2/2015)... 2015 Research ... the addition of Jain PharmaBiotech,s new report ... to their offering. The ... fluorescence in situ hybridization (FISH), comparative genomic ... includes application of nanobiotechnology, microarrays, real-time polymerase ...
Breaking Biology Technology:NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 2NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 3NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 4NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 5NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 6NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 7Global Biochips and Microarrays Technologies, Markets and Companies Report 2015 with Market Size in 2014 and Projected Value for the Years 2019 and 2024 2Updated 2015 Biomarkers Report - Latest Technologies, Markets and Companies Insights to 2024 with over 1,000 References 2Updated 2015 Biomarkers Report - Latest Technologies, Markets and Companies Insights to 2024 with over 1,000 References 3Global Cytogenetics Technologies Study 2015-2025 - Latest Markets and Companies Analysis 2Global Cytogenetics Technologies Study 2015-2025 - Latest Markets and Companies Analysis 3
... Inc. (NYSE: CRY ), and BioForm Medical, Inc. ... a CE Mark for the use of CryoLife,s,BioGlue Surgical ... a reconstructive plastic surgery procedure. The CE,Mark approval allows ... BioGlue will be distributed by CryoLife,s partner BioForm ...
... Environmental,Tectonics Corporation,s (Amex: ETC ) ("ETC" or ... of seven (7) BARA-MED(R) XD,Monoplace Hyperbaric Chambers to ... associated with Haelen Hyperbarics., ETC is delighted ... of,physician operated Hyperbaric Oxygen Therapy (HBOT) clinics. Haelen,Hyperbarics ...
... Also Completes FDA Submission for Removal of Clinical ... Genta,Incorporated (OTC Bulletin Board: GNTA) announced that the ... patents from the European,Patent Office for its pipeline ... to composition of matter for the tesetaxel drug,substance ...
Cached Biology Technology:CryoLife's BioGlue(R) Surgical Adhesive Receives European Approval for use in Browlift Cosmetic and Reconstructive Plastic Surgery 2CryoLife's BioGlue(R) Surgical Adhesive Receives European Approval for use in Browlift Cosmetic and Reconstructive Plastic Surgery 3CryoLife's BioGlue(R) Surgical Adhesive Receives European Approval for use in Browlift Cosmetic and Reconstructive Plastic Surgery 4Environmental Tectonics Corporation's BioMedical Systems Division Awarded Contract for Multiple Monoplace Chambers 2Environmental Tectonics Corporation's BioMedical Systems Division Awarded Contract for Multiple Monoplace Chambers 3Genta Receives Notice of Allowances for European Patents Related to Composition and Processes for Tesetaxel, a Leading Oral Taxane 2Genta Receives Notice of Allowances for European Patents Related to Composition and Processes for Tesetaxel, a Leading Oral Taxane 3Genta Receives Notice of Allowances for European Patents Related to Composition and Processes for Tesetaxel, a Leading Oral Taxane 4
(Date:7/31/2015)... 2015 Den 10. internationale konference om Genomik ... 22. - 25. oktober i Shenzhen ... fødselsdag i år. Siden starten i 2006 er ICB ... ,omik,-feltet, og er en af de mest dynamiske, entusiastiske ... på nylige gennembrud og fremskridt inden for ,omik,-forskning, som ...
(Date:7/31/2015)... , 31 de julho de 2015 A ... www.icg-10.org ) será realizada pela BGI de 22-25 de outubro ... A conferência está celebrando seu 10 o. ... a ICG se tornou uma das reuniões mais influentes ... encontros científicos mais dinâmicos, entusiastas e prazerosos. ...
(Date:7/31/2015)... 31 de julio de 2015 La 10 th ... celebrará por medio de BGI del 22 al 25 de octubre ... Este año, la conferencia celebra su décimo aniversario. ... convertido en una de las reuniones anuales más influyentes del ... las reuniones más dinámicas, entusiastas y mejores a nivel científico. ...
Breaking Biology News(10 mins):Den 10. internationale konference om Genomics (ICG-10) åbner i oktober 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 3La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 2La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 3
... researchers say they have found ,missing heat, in the climate ... or stopped over the past decade. , Observational data ... cent of the planet with Polar regions and parts ... scientist at the University of York, and Robert Way, a ...
... (November 13, 2013) Scientists from the New York ... Medical Center (CUMC) have used stem cells created from ... diabetesWolfram syndrometo elucidate an important biochemical pathway for beta-cell ... colleagues were published today in Diabetes . ...
... provider of scientific, technical and medical information products and services, ... the first full open access journal within the Biochimica ... BBA Clinical will focus on translating molecular ... is a biomedical journal dedicated to publishing research on ...
Cached Biology News:'Missing heat' discovery prompts new estimate of global warming 2Human stem cells used to elucidate mechanisms of beta-cell failure in diabetes 2Human stem cells used to elucidate mechanisms of beta-cell failure in diabetes 3Elsevier's Biochimica et Biophysica Acta (BBA) journal series adds open access journal: BBA Clinical 2
... and ES1301 mutS are mismatch repair minus ... strains prevents repair of the newly synthesized ... efficiencies and making them helpful in such ... II Mutagenesis Systems. Both ES1301 and BMH ...
propidium iodide *1.0 mg/mL solution in water*...
Applications: (+) Immunocytochemistry and immunohistochemistry...
MOUSE ANTI RAT KAPPA/LAMBDA:HRP Immunogen: MARK-1: Rat kappa light chains (IR202 and IR968)MARL-15: Rat lambda light chains (RH58, IR31)...
Biology Products: